MovDisordV3, PascalFrancis, Curation, bibRecord, 001484

Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan

Identifieur interne : 001484 ( PascalFrancis/Curation ); précédent : 001483; suivant : 001485

Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan

Auteurs : Christopher G. Goetz [États-Unis] ; Stanley Fahn [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Matthew B. Stern [États-Unis] ; Barbara C. Tilley [États-Unis] ; Richard Dodel [Allemagne] ; Bruno Dubois [France] ; Robert Holloway [États-Unis] ; Joseph Jankovic [États-Unis] ; Jaime Kulisevsky [Espagne] ; Anthony E. Lang [Canada] ; Andrew Lees [Royaume-Uni] ; Sue Leurgans [États-Unis] ; Peter A. Lewitt [États-Unis] ; David Nyenhuis [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Anette Schrag [Royaume-Uni] ; Jeanne A. Teresi [États-Unis] ; Jacobus J. Van Hilten [Pays-Bas] ; Nancy Lapelle [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0133215

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Myélodysplasique syndrome, Révision, Echelle d'évaluation.

English descriptors

KwdEn :
- Evaluation scale, Myelodysplastic syndrome, Nervous system diseases, Parkinson disease, Revision.

Abstract

This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan`
A11	`01`	`1`		`@1 GOETZ (Christopher G.)`
A11	`02`	`1`		`@1 FAHN (Stanley)`
A11	`03`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`04`	`1`		`@1 POEWE (Werner)`
A11	`05`	`1`		`@1 SAMPAIO (Cristina)`
A11	`06`	`1`		`@1 STEBBINS (Glenn T.)`
A11	`07`	`1`		`@1 STERN (Matthew B.)`
A11	`08`	`1`		`@1 TILLEY (Barbara C.)`
A11	`09`	`1`		`@1 DODEL (Richard)`
A11	`10`	`1`		`@1 DUBOIS (Bruno)`
A11	`11`	`1`		`@1 HOLLOWAY (Robert)`
A11	`12`	`1`		`@1 JANKOVIC (Joseph)`
A11	`13`	`1`		`@1 KULISEVSKY (Jaime)`
A11	`14`	`1`		`@1 LANG (Anthony E.)`
A11	`15`	`1`		`@1 LEES (Andrew)`
A11	`16`	`1`		`@1 LEURGANS (Sue)`
A11	`17`	`1`		`@1 LEWITT (Peter A.)`
A11	`18`	`1`		`@1 NYENHUIS (David)`
A11	`19`	`1`		`@1 OLANOW (C. Warren)`
A11	`20`	`1`		`@1 RASCOL (Olivier)`
A11	`21`	`1`		`@1 SCHRAG (Anette)`
A11	`22`	`1`		`@1 TERESI (Jeanne A.)`
A11	`23`	`1`		`@1 VAN HILTEN (Jacobus J.)`
A11	`24`	`1`		`@1 LAPELLE (Nancy)`
A14	`01`			`@1 Department of Neurological Sciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 1 aut. @Z 6 aut. @Z 16 aut.`
A14	`02`			`@1 Department of Neurology, Columbia University @2 New York, New York @3 USA @Z 2 aut.`
A14	`03`			`@1 Department of Neuroepidemiology, Carlos III Institute @2 Madrid @3 ESP @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Innsbruck Medical University @2 Innsbruck @3 AUT @Z 4 aut.`
A14	`05`			`@1 Department of Pharmacology, Faculdade de Medicina de Lisboa @2 Lisboa @3 PRT @Z 5 aut.`
A14	`06`			`@1 Department of Neurology, University of Pennsylvania @2 Philadelphia, Pennsylvania @3 USA @Z 7 aut.`
A14	`07`			`@1 Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina @2 Charleston, South Carolina @3 USA @Z 8 aut.`
A14	`08`			`@1 Department of Neurology, Friedrich-Wilhelms University @2 Bonn @3 DEU @Z 9 aut.`
A14	`09`			`@1 Department of Neurology, Hôpital de la Salpetriere @2 Paris @3 FRA @Z 10 aut.`
A14	`10`			`@1 Department of Neurology, University of Rochester @2 Rochester, New York @3 USA @Z 11 aut.`
A14	`11`			`@1 Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 12 aut.`
A14	`12`			`@1 Department of Neurology, Sant Pau Hospital @2 Barcelona @3 ESP @Z 13 aut.`
A14	`13`			`@1 Division of Applied and Interventional Research, University of Toronto @2 Toronto @3 CAN @Z 14 aut.`
A14	`14`			`@1 Reta Lila Weston Institute of Neurological Studies, University College @2 London, England @3 GBR @Z 15 aut.`
A14	`15`			`@1 Department of Neurology, Wayne State University @2 Detroit, Michigan @3 USA @Z 17 aut.`
A14	`16`			`@1 Department of Neurology and Rehabilitation, University of Illinois @2 Chicago, Illinois @3 USA @Z 18 aut.`
A14	`17`			`@1 Department of Neurology, Mount Sinai School of Medicine @2 New York, New York @3 USA @Z 19 aut.`
A14	`18`			`@1 Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University @2 Toulouse @3 FRA @Z 20 aut.`
A14	`19`			`@1 Department of Clinical Neurosciences, University College @2 London, England @3 GBR @Z 21 aut.`
A14	`20`			`@1 Division of General Medicine, Columbia University @2 New York, New York @3 USA @Z 22 aut.`
A14	`21`			`@1 Department of Neurology, Leiden University @2 Leiden @3 NLD @Z 23 aut.`
A14	`22`			`@1 Division of Preventive and Behavioral Medicine, University of Massachusetts @2 Worcester, Massachusetts @3 USA @Z 24 aut.`
A20				`@1 41-47`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000145483830060`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 6 ref.`
A47	`01`	`1`		`@0 07-0133215`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A01`
C02	`04`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Myélodysplasique syndrome @5 03`
C03	`03`	`X`	`ENG`	`@0 Myelodysplastic syndrome @5 03`
C03	`03`	`X`	`SPA`	`@0 Mielodisplastico síndrome @5 03`
C03	`04`	`X`	`FRE`	`@0 Révision @5 09`
C03	`04`	`X`	`ENG`	`@0 Revision @5 09`
C03	`04`	`X`	`SPA`	`@0 Revisión @5 09`
C03	`05`	`X`	`FRE`	`@0 Echelle d'évaluation @5 10`
C03	`05`	`X`	`ENG`	`@0 Evaluation scale @5 10`
C03	`05`	`X`	`SPA`	`@0 Escala evaluación @5 10`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Hémopathie maligne @5 41`
C07	`05`	`X`	`ENG`	`@0 Malignant hemopathy @5 41`
C07	`05`	`X`	`SPA`	`@0 Hemopatía maligna @5 41`
N21				`@1 085`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001837

Links to Exploration step

Pascal:07-0133215

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neuroepidemiology, Carlos III Institute</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C." last="Tilley">Barbara C. Tilley</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1>
<s2>Charleston, South Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology, Friedrich-Wilhelms University</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Hôpital de la Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Holloway, Robert" sort="Holloway, Robert" uniqKey="Holloway R" first="Robert" last="Holloway">Robert Holloway</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Neurology, University of Rochester</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Neurology, Sant Pau Hospital</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Applied and Interventional Research, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Reta Lila Weston Institute of Neurological Studies, University College</s1>
<s2>London, England</s2>
<s3>GBR</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Department of Neurology, Wayne State University</s1>
<s2>Detroit, Michigan</s2>
<s3>USA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Nyenhuis, David" sort="Nyenhuis, David" uniqKey="Nyenhuis D" first="David" last="Nyenhuis">David Nyenhuis</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Department of Neurology and Rehabilitation, University of Illinois</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><inist:fA14 i1="19"><s1>Department of Clinical Neurosciences, University College</s1>
<s2>London, England</s2>
<s3>GBR</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Teresi, Jeanne A" sort="Teresi, Jeanne A" uniqKey="Teresi J" first="Jeanne A." last="Teresi">Jeanne A. Teresi</name>
<affiliation wicri:level="1"><inist:fA14 i1="20"><s1>Division of General Medicine, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Van Hilten, Jacobus J" sort="Van Hilten, Jacobus J" uniqKey="Van Hilten J" first="Jacobus J." last="Van Hilten">Jacobus J. Van Hilten</name>
<affiliation wicri:level="1"><inist:fA14 i1="21"><s1>Department of Neurology, Leiden University</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>23 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Lapelle, Nancy" sort="Lapelle, Nancy" uniqKey="Lapelle N" first="Nancy" last="Lapelle">Nancy Lapelle</name>
<affiliation wicri:level="1"><inist:fA14 i1="22"><s1>Division of Preventive and Behavioral Medicine, University of Massachusetts</s1>
<s2>Worcester, Massachusetts</s2>
<s3>USA</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0133215</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0133215 INIST</idno>
<idno type="RBID">Pascal:07-0133215</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001837</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001484</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neuroepidemiology, Carlos III Institute</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C." last="Tilley">Barbara C. Tilley</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1>
<s2>Charleston, South Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology, Friedrich-Wilhelms University</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Hôpital de la Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Holloway, Robert" sort="Holloway, Robert" uniqKey="Holloway R" first="Robert" last="Holloway">Robert Holloway</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Neurology, University of Rochester</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Neurology, Sant Pau Hospital</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Division of Applied and Interventional Research, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Reta Lila Weston Institute of Neurological Studies, University College</s1>
<s2>London, England</s2>
<s3>GBR</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Department of Neurology, Wayne State University</s1>
<s2>Detroit, Michigan</s2>
<s3>USA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Nyenhuis, David" sort="Nyenhuis, David" uniqKey="Nyenhuis D" first="David" last="Nyenhuis">David Nyenhuis</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Department of Neurology and Rehabilitation, University of Illinois</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><inist:fA14 i1="19"><s1>Department of Clinical Neurosciences, University College</s1>
<s2>London, England</s2>
<s3>GBR</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Teresi, Jeanne A" sort="Teresi, Jeanne A" uniqKey="Teresi J" first="Jeanne A." last="Teresi">Jeanne A. Teresi</name>
<affiliation wicri:level="1"><inist:fA14 i1="20"><s1>Division of General Medicine, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Van Hilten, Jacobus J" sort="Van Hilten, Jacobus J" uniqKey="Van Hilten J" first="Jacobus J." last="Van Hilten">Jacobus J. Van Hilten</name>
<affiliation wicri:level="1"><inist:fA14 i1="21"><s1>Department of Neurology, Leiden University</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>23 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Lapelle, Nancy" sort="Lapelle, Nancy" uniqKey="Lapelle N" first="Nancy" last="Lapelle">Nancy Lapelle</name>
<affiliation wicri:level="1"><inist:fA14 i1="22"><s1>Division of Preventive and Behavioral Medicine, University of Massachusetts</s1>
<s2>Worcester, Massachusetts</s2>
<s3>USA</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evaluation scale</term>
<term>Myelodysplastic syndrome</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Revision</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Myélodysplasique syndrome</term>
<term>Révision</term>
<term>Echelle d'évaluation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FAHN (Stanley)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>STERN (Matthew B.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>TILLEY (Barbara C.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DODEL (Richard)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>DUBOIS (Bruno)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>HOLLOWAY (Robert)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>JANKOVIC (Joseph)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>KULISEVSKY (Jaime)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>LEES (Andrew)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>LEURGANS (Sue)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>LEWITT (Peter A.)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>NYENHUIS (David)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>OLANOW (C. Warren)</s1>
</fA11>
<fA11 i1="20" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="21" i2="1"><s1>SCHRAG (Anette)</s1>
</fA11>
<fA11 i1="22" i2="1"><s1>TERESI (Jeanne A.)</s1>
</fA11>
<fA11 i1="23" i2="1"><s1>VAN HILTEN (Jacobus J.)</s1>
</fA11>
<fA11 i1="24" i2="1"><s1>LAPELLE (Nancy)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neuroepidemiology, Carlos III Institute</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1>
<s2>Charleston, South Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Neurology, Friedrich-Wilhelms University</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurology, Hôpital de la Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Neurology, University of Rochester</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Neurology, Sant Pau Hospital</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Division of Applied and Interventional Research, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Reta Lila Weston Institute of Neurological Studies, University College</s1>
<s2>London, England</s2>
<s3>GBR</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Department of Neurology, Wayne State University</s1>
<s2>Detroit, Michigan</s2>
<s3>USA</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Department of Neurology and Rehabilitation, University of Illinois</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="17"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="18"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse University</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>20 aut.</sZ>
</fA14>
<fA14 i1="19"><s1>Department of Clinical Neurosciences, University College</s1>
<s2>London, England</s2>
<s3>GBR</s3>
<sZ>21 aut.</sZ>
</fA14>
<fA14 i1="20"><s1>Division of General Medicine, Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
</fA14>
<fA14 i1="21"><s1>Department of Neurology, Leiden University</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>23 aut.</sZ>
</fA14>
<fA14 i1="22"><s1>Division of Preventive and Behavioral Medicine, University of Massachusetts</s1>
<s2>Worcester, Massachusetts</s2>
<s3>USA</s3>
<sZ>24 aut.</sZ>
</fA14>
<fA20><s1>41-47</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000145483830060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>6 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0133215</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A01</s0>
</fC02>
<fC02 i1="04" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Myélodysplasique syndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Myelodysplastic syndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Mielodisplastico síndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Révision</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Revision</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Revisión</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Echelle d'évaluation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Evaluation scale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Escala evaluación</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s5>41</s5>
</fC07>
<fN21><s1>085</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001484 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001484 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0133215
   |texte=   Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan

Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri